| Display title | Chemistry:Vosaroxin |
| Default sort key | Vosaroxin |
| Page length (in bytes) | 2,591 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 11520 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>QCDvac |
| Date of page creation | 16:23, 5 May 2022 |
| Latest editor | imported>QCDvac |
| Date of latest edit | 16:23, 5 May 2022 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Vosaroxin (AG-7352, SPC-595, SNS 595, voreloxin) is a topoisomerase II inhibitor causing site-selective DNA damage. It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis. |
